Review of Global Policy Architecture and Country Level Practice on HIV/AIDS and Drug Treatment

R. Ali, D. Burrows, L. Gowing, R. Vial, N. Walsh, Pacifica Onyancha, E. Finnerty
{"title":"Review of Global Policy Architecture and Country Level Practice on HIV/AIDS and Drug Treatment","authors":"R. Ali, D. Burrows, L. Gowing, R. Vial, N. Walsh, Pacifica Onyancha, E. Finnerty","doi":"10.2139/ssrn.1357336","DOIUrl":null,"url":null,"abstract":"This review, funded by the U.K Department for International Development, provides an understanding of the gaps and opportunities for improving access to drug treatment, in particular opioid substitution treatment (OST), for drug users affected and infected by HIV. OST is effective in treating opioid dependency, reducing its individual and social costs. For HIV-infected, opioid-dependent injecting drug users, consistent participation in OST is associated with a higher probability of antiretroviral treatment and, amongst antiretroviral users, more consistent use of antiretrovirals. At the global policy level, there are few barriers to the introduction and expansion of OST with both methadone and buprenorphine now on the WHO Essential Drugs List, and all relevant international organisations approving and encouraging the use of OST for HIV prevention, treatment, care and support in countries where injecting drug use and HIV are found. Unfortunately, there are huge disparities in access to drug treatment, with participation in treatment in Asia and Africa being disturbingly low. Country reports from Vietnam, Kyrgyzstan and Kenya provide examples of the barriers and successes on the ground. Recommendations for donors, international organizations and public health champions include:1. Strengthen leadership at global level for access to drug treatment and, in particular, opioid substitution therapy as a key intervention in HIV prevention, treatment and care among injecting drug users. 2. Develop audit tools for donors to ensure that consideration of harm reduction interventions, prioritizing OST and needle-syringe programmes, becomes a standard part of all development work related to HIV/AIDS. 3. Support the implementation of drug treatment and, in particular, OST in country. 4. Integrate drug treatment and, in particular, OST with HIV treatment. 5. Establish comparable drug treatment programs within correctional institutions to those in the community.","PeriodicalId":105371,"journal":{"name":"Public Health Law & Policy","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2009-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Law & Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.1357336","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This review, funded by the U.K Department for International Development, provides an understanding of the gaps and opportunities for improving access to drug treatment, in particular opioid substitution treatment (OST), for drug users affected and infected by HIV. OST is effective in treating opioid dependency, reducing its individual and social costs. For HIV-infected, opioid-dependent injecting drug users, consistent participation in OST is associated with a higher probability of antiretroviral treatment and, amongst antiretroviral users, more consistent use of antiretrovirals. At the global policy level, there are few barriers to the introduction and expansion of OST with both methadone and buprenorphine now on the WHO Essential Drugs List, and all relevant international organisations approving and encouraging the use of OST for HIV prevention, treatment, care and support in countries where injecting drug use and HIV are found. Unfortunately, there are huge disparities in access to drug treatment, with participation in treatment in Asia and Africa being disturbingly low. Country reports from Vietnam, Kyrgyzstan and Kenya provide examples of the barriers and successes on the ground. Recommendations for donors, international organizations and public health champions include:1. Strengthen leadership at global level for access to drug treatment and, in particular, opioid substitution therapy as a key intervention in HIV prevention, treatment and care among injecting drug users. 2. Develop audit tools for donors to ensure that consideration of harm reduction interventions, prioritizing OST and needle-syringe programmes, becomes a standard part of all development work related to HIV/AIDS. 3. Support the implementation of drug treatment and, in particular, OST in country. 4. Integrate drug treatment and, in particular, OST with HIV treatment. 5. Establish comparable drug treatment programs within correctional institutions to those in the community.
关于艾滋病毒/艾滋病和药物治疗的全球政策架构和国家一级实践审查
这项审查由英国国际发展部资助,提供了对改善受艾滋病毒影响和感染的吸毒者获得药物治疗,特别是阿片类药物替代治疗(OST)的差距和机会的了解。OST在治疗阿片类药物依赖方面是有效的,降低了其个人和社会成本。对于感染艾滋病毒、依赖阿片类药物的注射吸毒者而言,持续参加口服避孕药服务与获得抗逆转录病毒治疗的可能性较高有关,而且在抗逆转录病毒使用者中,更持续地使用抗逆转录病毒药物。在全球政策层面,由于美沙酮和丁丙诺啡现已列入世卫组织基本药物清单,所有相关国际组织都批准并鼓励在发现注射吸毒和艾滋病毒的国家将口服药物用于艾滋病毒的预防、治疗、护理和支持,因此在引进和扩大口服药物治疗方面几乎没有什么障碍。不幸的是,在获得药物治疗方面存在巨大差异,亚洲和非洲的治疗参与率低得令人不安。来自越南、吉尔吉斯斯坦和肯尼亚的国家报告提供了实地障碍和成功的例子。对捐助者、国际组织和公共卫生倡导者的建议包括:加强全球一级在获得药物治疗,特别是阿片类药物替代疗法方面的领导,将其作为注射吸毒者预防、治疗和护理艾滋病毒的一项关键干预措施。2. 为捐助者开发审计工具,以确保考虑减少危害干预措施,优先考虑OST和针头注射器方案,成为与艾滋病毒/艾滋病有关的所有发展工作的标准部分。3.支持在国家实施药物治疗,特别是OST。4. 将药物治疗,特别是OST与艾滋病毒治疗结合起来。5. 在惩教机构内建立与社区内类似的戒毒治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信